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Background: Recommended screening policies for cervical
cancer differ widely among countries with respect to tar-
geted age range, screening interval, and total number of
scheduled screening examinations (i.e., Pap smears). We
compared the efficiency of cervical cancer-screening pro-
grams by performing a cost-effectiveness analysis of cervical
cancer-screening policies from high-income countries.
Methods: We used the microsimulation screening analysis
(MISCAN) program to model and determine the costs and
effects of almost 500 screening policies, some fictitious and
some actual (i.e., recommended by national guidelines). The
costs (in U.S. dollars) and effects (in years of life gained)
were compared for each policy to identify the most efficient
policies. Results: There were 15 efficient screening policies
(i.e., no alternative policy exists that results in more life-
years gained for lower costs). For these policies, which
considered two to 40 total scheduled examinations, the age
range expanded gradually from 40–52 years to 20–80 years
as the screening interval decreased from 12 to 1.5 years. For
the efficient policies, the predicted gain in life expectancy
ranged from 11.6 to 32.4 days, compared with a gain of 46
days if cervical cancer mortality were eliminated entirely.
The average cost-effectiveness ratios increased from $6700
(for the longest screening interval) to $23 900 per life-year
gained. For some countries, the recommended screening
policies were close to efficient, but the cost-effectiveness
could be improved by reducing the number of scheduled
examinations, starting them at later ages, or lengthening the
screening interval. Conclusions: The basis for the diversity in
the screening policies among high-income countries does not
appear to relate to the screening policies’ cost-effectiveness
ratios, which are highly sensitive to the number of Pap
smears offered during a lifetime. [J Natl Cancer Inst 2002;
94:193–204]
The purpose of cervical cancer screening with the Pap smear
test is to detect preinvasive cancers and to prevent subsequent
death from the disease. Although no randomized, controlled tri-
als on mortality reduction from cervical cancer screening have
been performed, there is ample evidence that screening has led
to a reduction in cancer-related mortality (1–4). In the high-
income countries of Western Europe, North America, and Aus-
tralia, preventive Pap smear tests are performed on a large scale
in organized, often invitation-based, programs and by the per-
sonal initiative of individual women and physicians or practi-
tioners. The screening recommendations and official policies in
different countries and regions show considerable variation. For
example, in The Netherlands and Finland, the recommended
number of Pap smears during a woman’s lifetime is seven,
whereas in Germany and Australia, the recommended number is
more than 25. In addition, in the U.K., The Netherlands, and
Finland, the recommended time interval between screening ex-
aminations is 5 years, whereas in Australia it is 2 years and in
Germany it is 1 year. There are also differences in the target age
range. For example, in The Netherlands, screening is offered
between the ages of 30 and 60 years (before 1996, screening was
offered between the ages of 35 and 53 years), whereas in Aus-
tralia screening is recommended between the ages of 18 and
70 years (5).
How much the differences in the recommendations alter the
cost effectiveness of the screening policies is unclear. The
method of choice for the evaluation and comparison of different
health care policies is cost-effectiveness analysis, which, for
cervical cancer screening, involves a comparison of different
screening policies that consider screening costs, possible savings
in treatment, and potential health effects, such as life-years
gained and cervical cancer deaths prevented. Such a comparison
of policies would lead to the identification of efficient policies
for which no alternative policies currently exist that result in
more life-years gained for lower costs. In the rational decision-
making process for making cervical cancer-screening recom-
mendations, a policy maker can compare the incremental and/or
average costs per life-year gained of the efficient policies with
the maximum allowed values or thresholds for the incremental
and/or average costs per life-year gained and identify the most
efficient screening policy given the available resources.
In this study, the microsimulation screening analysis (MISCAN)
model (6,7) for cervical cancer screening was used to evaluate
and compare almost 500 screening policies that differed with
respect to the recommended number of screenings, screening
intervals, and targeted age ranges. These screening policies con-
sist of fictitious screening policies, policies used in countries
with a cervical screening program or in which screening was
recommended in national guidelines (5,8–13), policies recom-
mended in the literature (14), and policies found to be cost-
effective in other studies (2,15–21). We estimated the life-years
gained and the costs of the policies and identified efficient
screening policies. We determined the best policy for different
thresholds for the incremental costs per life-year gained. The
results were compared with existing policies and recommenda-
tions and with policies that have emerged from other cost-
effectiveness analyses (2,15–21). Our analysis uses demo-
graphic, epidemiologic, screening, and treatment characteristics
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from The Netherlands. Because these characteristics may
be different for other countries, we investigated the extent to
which differences in demographic, epidemiologic, screening,
and treatment characteristics result in differences in screening
recommendations.
METHODS
Policies
The fictitious screening policies considered in this cost-
effectiveness analysis are listed in Supplementary Table 1
(available at the Journal’s Web site http://jnci.oupjournals.org).
We also included screening policies used in countries with cer-
vical screening programs or recommended in national guidelines
(5,8–13) and screening policies considered in other cost-
effectiveness analyses (2,15–21).
MISCAN
Costs and effects for the different screening policies were
estimated using MISCAN (6,7). The MISCAN simulation
program was developed at the Department of Public Health,
Erasmus University Rotterdam, The Netherlands, and has been
used to evaluate breast, cervical, colon, and prostate cancer-
screening programs. In MISCAN, a comparison is made be-
tween the situation with and without screening. A large popu-
lation (i.e., 40 million women) is generated. This population
consists of fictitious individual life histories, in which some of
the women may develop cancer and some may die of the disease.
This results in an age-specific and time-specific output of cancer
incidence and mortality. This fictitious population then under-
goes simulated screening. Screening may change some of the
life histories. For example, in some life histories, preclinical
lesions will be detected by screening, which may prevent further
development of the disease and subsequent cancer-related death.
The aggregated changes in all of the life histories constitute the
effectiveness of the screening program. The cervical model
specifications used as input for the MISCAN program include
the demographic characteristics, the epidemiology and natural
history of the disease, the screening characteristics, and the
costs. A detailed description of the MISCAN program is given
elsewhere (6,7).
Model Specifications: Demography and Epidemiology
The Dutch population at risk for cervical cancer was simu-
lated from demographic data (22) and hysterectomy (for reasons
other than cervical cancer) rates that were obtained from the
National Hospital Admission Registration (23).
The background risk, i.e., the risk of dying of cervical cancer
in a situation without screening, of cervical cancer-related mor-
tality was derived from an age–period cohort analysis (24). For
our analyses, we assumed that the lifetime background risk of
developing cervical cancer (or its progressive precursors) was
proportional to the estimated relative level of cervical cancer
mortality for each birth cohort. Furthermore, we assumed that
there was a fixed ratio in each birth cohort between the lifetime
risks of preinvasive disease that will spontaneously regress and
preinvasive disease that will progress to cervical cancer. The
cumulative incidence of progressive preinvasive cervical cancer
by birth cohort was 0.0229 for those born from 1889 through
1918, 0.0235 for those born from 1919 through 1928, 0.0128 for
those born from 1929 through 1938, 0.0106 for those born from
1939 through 1948, and 0.0148 for those born from 1949
through 2000.
For our analyses, we considered the reported negative asso-
ciation between attendance to the screening program and risk of
cervical cancer (25–27) by subdividing the simulated population
into two risk strata: 90% of the women were assumed to be
potential attenders and were assumed to have a low risk of
developing cervical cancer, and the remaining 10% of the popu-
lation was assumed to be persistent nonattenders. On the basis of
results from British Columbia in which the risk of attenders was
estimated at 0.74 of the average risk (27), we assumed that the
persistent nonattenders have a risk of cervical cancer three times
higher than that of the attenders.
The age distribution of the incidence of progressive preinva-
sive neoplasia was determined with the use of the age compo-
nents of the mortality derived from the age–period cohort analy-
sis (24), the distribution of the duration of the preclinical stages
of the disease, and the duration between clinical diagnosis and
death combined with the age-specific lethality from cervical
cancer. The age distribution of the incidence of regressive pre-
invasive neoplasia was calibrated by calculating the difference
between observed cervical intraepithelial neoplasia (CIN) detec-
tion rates in The Netherlands (derived from the Dutch Network
and National Database for Pathology [PALGA] data for the year
1992) and the detection rates of progressive CIN predicted by
MISCAN. The resulting age distributions of preinvasive inci-
dence of regressive and progressive disease, respectively, are
shown in Supplementary Table 2 (available at the Journal’s Web
site http://jnci.oupjournals.org).
Preclinical disease is subdivided into four sequential stages
(Supplementary Fig. 1; available at the Journal’s Web site http://
jnci.oupjournals.org): preinvasive (corresponding to CIN; the
stage in which the disease is not yet invasive and spontaneous
regression may occur) and the three preclinical invasive stages,
i.e., the stages in which the disease has become invasive but is
not yet detected [International Federation of Gynecology and
Obstetrics definitions IA, IB, and II+; (28)]. A Weibull distri-
bution was used to assume variation between women in the
duration of the different preinvasive and preclinical disease
stages (27). The mean duration and the standard deviation of the
different stages were 11.8 ± 2.2 years for preinvasive stage CIN,
2.0 ± 0.9 years for preclinical invasive stage IA, and 1.9 ± 0.9
years for preclinical invasive stages IB and II+ combined. Pro-
gressive and regressive preinvasive stages were assumed to have
the same duration distribution. The mean duration and the stan-
dard deviation of the preinvasive stages were estimated from
British Columbia screening data that used one combined CIN
stage (27). Regressive lesions never become invasive and will
return to normal (without evidence of cervical neoplasia) after
the preinvasive stage. After progressive preinvasive lesions be-
come macroinvasive (stage IB), some will be clinically diag-
nosed, whereas others will progress to stage II+ before any
symptoms develop. The mean duration of the preclinical inva-
sive stage was based on the ratio of the prevalence to clinical
incidence before screening began in British Columbia (27,29)
and in a Dutch pilot study (30). In the Dutch pilot study, 54% of
the invasive cancers detected at the prevalent screen (i.e., the
first screening in a previously unscreened population) were di-
agnosed with stage IA disease; this indicates that the duration of
preclinical stage IA compared with preclinical stages IB and II+
is about the same. For our analyses, we assumed [on the basis of
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data from Dutch hospital registries (31) and from the Norwegian
cancer registry (32)] that the proportion of clinical cancers that
are diagnosed in stage IB decreased linearly from 58% at age
30 years to 26% at age 70 years.
Model Specifications: Screening and Treatment
The simulated screening policies were assumed to start in
1993 and to continue for 27 years until 2020. Screening practices
before 1993, however, will influence the effectiveness of the
screening program after 1993; therefore, this practice has been
included in the simulation of the Dutch situation.
Information on the screening activities before 1993 was ob-
tained from survey data (24,33,34). The attendance rate from
1993 onward was assumed to be 80% until age 50 years and to
decrease by 0.5% per year thereafter. Because we assumed that
10% of the population will never attend the screening program,
we calculated a probability of 88.9% for the potential attenders,
which constituted 90% of the population, to actually respond to
a scheduled screening examination. After age 50 years, the at-
tendance rate was assumed to decrease by 0.5% per year. This is
in accordance with the percentage of women in The Netherlands
who had a Pap smear from 1990 through 1994.
The sensitivity of the Pap smear for different disease stages is
80% for preinvasive CIN (27), 85% for preclinical invasive
stages IA and IB, and 90% for preclinical invasive stage II+.
False-positive test results indicate the specificity of the Pap
smear. We assumed that 0.06% of screening attenders were re-
ferred for a colposcopy and a biopsy after which no cervical
neoplasia was found and that 6.2% of screening attenders will,
on average, have 1.8 repeat smears because of borderline test
results after their primary smear before they return to the regular
screening schedule (PALGA 1992).
For the simulation model, the percentage of women surviving
after a clinical diagnosis of cancer was assumed to be age de-
pendent and stage dependent on the basis of Dutch incidence and
mortality figures from the prescreening period in The Nether-
lands (24). Cancers clinically detected in stage IB have a more
favorable prognosis than cancers detected in stage II+, and
women aged 30–50 years who are diagnosed with stage II+
disease have a higher probability of surviving than women di-
agnosed with the same disease when younger than 30 years or
older than 50 years (Supplementary Table 3 available at the
Journal’s Web site http://jnci.oupjournals.org).
Screen-detected preinvasive lesions were assumed to lead to
a 100% cure rate. For screen-detected invasive cancers, the sur-
vival was modeled as a reduction in the risk of dying of cervical
cancer compared with that of dying of clinically diagnosed can-
cer. This reduction was assumed to be 80% for screen-detected
stage IA disease, a percentage that was found to reproduce the
reported 97% 5-year relative survival for this stage (35). For
screen-detected stage II+ disease, the reduction was fixed at
20%, resulting from a comparison of the stage distribution
within stage II+ in a period with little screening (1970–1975)
to the stage distribution within screen-detected II+ cases (30).
For screen-detected stage IB disease, the reduction was assumed
to be 40%, an intermediate value.
Model Specifications: Costs
The costs of a screening program (Supplementary Table 4
available at the Journal’s Web site http://jnci.oupjounals.org)
were divided into fixed costs and variable costs. Fixed costs are
associated with coordinating and evaluating a cervical cancer-
screening program. Variable costs are divided into invitation
costs and screening costs. Screening costs include time and
travel costs for the woman, costs of smear taking, costs of cy-
tologic evaluation, costs of registration in the PALGA, and the
costs of 5.3% (estimated from PALGA data for the year 1992) of
the smears that are repeated because of inadequate smears or
smears without endocervical cells (36,37).
The costs of diagnostic and treatment procedures for the dif-
ferent disease stages and the costs of treatment and palliative
care for advanced cervical cancer in the last phase before dying
of cervical cancer were derived from cost studies in The Neth-
erlands (24,36,38,39).
Cost-Effectiveness Analysis
In this study, MISCAN was used to predict costs and effects
for organized screening programs for a 27-year period. We as-
sumed a hypothetic situation in which the organized program is
the only screening program and in which no opportunistic
screening (i.e., spontaneous screening for other than medical
reasons) occurs. The simulated effects are accounted for until all
simulated women who could have benefited from the program
have died. The costs are presented in U.S. dollars (1 U.S. dollar
 2 Dutch florins). The effects are presented in days of life
gained per woman per year of the screening program. The cost-
effectiveness calculations are conducted from the societal per-
spective.
To identify efficient screening policies, we compared the
simulated costs of and life-years gained from each policy. A
policy was considered to be efficient when there was no alter-
native policy resulting in more life-years gained for the same or
lower costs (simple dominance) and when there was no combi-
nation of two other screening policies that gained more life-
years for the same costs (extended dominance) (40,41).
The effects per woman during her lifetime were derived by
multiplying the number of days gained per woman per year of
the screening program by the average life expectancy of a
woman in The Netherlands, which is 80 years (42). In the cal-
culation of incremental and/or average cost-effectiveness ratios,
both costs and effects were discounted at a rate of 3% to convert
future costs and health effects to their present value [i.e., dollars
expended or health effects experienced n years in the future are
discounted by a factor of 1/(1.03)n (41)], as recommended by the
Panel on Cost Effectiveness in Health and Medicine.
Because of the nature of microsimulations, estimates for costs
and effects are affected by random fluctuation. We calculated
this fluctuation to be less than 2% of the estimated value of the
cost-effectiveness ratio and up to 35% for the incremental cost-
effectiveness ratio. Therefore, to reduce the influence of random
fluctuation, the incremental cost-effectiveness ratio was esti-
mated by enlarging the simulated population 10 times to 400
million women.
Sensitivity Analysis
A one-way sensitivity analysis was performed on background
incidence, attendance, sensitivity (proportion of false-negative
tests) and specificity of the screening test, and costs (fixed costs,
screening costs, and assessment and treatment costs). The back-
ground incidence and fixed costs, screening costs, and treatment
costs were halved and doubled to obtain the low values and high
values, respectively, used in the sensitivity analysis. To deter-
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mine attendance, the lack of attendance values were halved and
doubled to obtain the high estimates and low estimates, respec-
tively. To determine the sensitivity of the screening test, we
halved and doubled the proportion of false-negative results for
all stages to obtain the high estimates and low estimates, respec-
tively. To determine the specificity of the screening test, we
obtained the high values by halving the percentage of repeat
smears because of borderline test results and the proportion of
referrals for biopsy after which no cervical neoplasia was found,
and the low values were obtained by doubling the baseline
estimates for these parameters.
RESULTS
Costs and Effects of Screening Policies
From nearly 500 screening policies, there was a broad range
of combinations of predicted costs and effects as measured by
life-years gained (Fig. 1). Per 1 000 000 women of the general
population, the costs varied between 0.5 million and 9.5 million
U.S. dollars, and the effects ranged from 50 life-years to 350
life-years gained per year of the screening program.
Next, after deleting those that were not efficient, we obtained
the efficient screening policies for which no alternative policy
exists that result in more life-years gained for lower costs. There
were 15 efficient screening policies, and together they repre-
sented the efficient frontier (Fig. 2). The age range of efficient
screening policies increased from age 40–52 years for policies
that recommend two examinations during a woman’s lifetime to
age 20–80 years for those that recommend more than 20 exami-
nations. In general, a more intensive screening policy was one
that recommended that screening start at a younger age, end at
an older age, and have a shorter interval between examinations
(Table 1). For the efficient policies, the effects of the total
screening program on life expectancy ranged from 11.6 days
for those that recommend two scheduled examinations during
a woman’s lifetime to 32.4 days for those that recommend 40
scheduled examinations. We estimated that total elimination of
cervical cancer would yield a gain in life expectancy of 46 days.
According to the law of diminishing returns, if the number of
scheduled examinations in a screening program were increased,
the increase in the number of life-years gained would slow
(Table 1). When a detailed assessment of the costs of a screening
program was compared with that of the costs of no screening,
screening costs were in excess of the costs of diagnostic testing
and treatment of preinvasive disease detected by screening com-
bined and were only partially compensated for by the savings
incurred from preventing invasive carcinoma and advanced dis-
ease (Table 2). Because the costs of coordinating and evaluating
the screening program were assumed to be independent of the
number of scheduled examinations, and because a scale effect
(i.e., the costs per smear are lower if more smears are performed)
was assumed for the costs per smear, the screening costs in-
creased less than proportionally with the number of scheduled
examinations. Moreover, when moving toward more intensive
policies, the incremental cost-effectiveness ratio increased be-
cause the incremental effects rapidly diminished (Table 1). For
a policy maker, if the decision regarding a policy depends only
on a maximal allowed value or threshold value for the incre-
mental costs per life-year gained, then for reference values of
$15 000, $30 000, and $60 000, screening policies with five, 10,
and 20 scheduled examinations, respectively, and screening
intervals of 9, 5, and 3 years, respectively, are optimal.
Sensitivity Analysis
Differences in demographic, epidemiologic, and screening
characteristics, such as background incidence, attendance, sen-
sitivity and specificity of the screening test, and cost, may lead
to different choices in efficient screening policies. The influ-
ences of these differences were investigated in a sensitivity
analysis (Table 3). A higher background incidence, i.e., the in-
cidence of invasive cancer in the hypothetic situation where
there has never been screening, led to higher effects of a screen-
ing policy because the effects were proportional to the incidence
of cervical cancer (see Table 3). This resulted in a more favor-
able incremental cost-effectiveness ratio, and consequently,
more intensive screening policies were feasible given a thresh-
old value for the incremental cost-effectiveness ratio.
Differences in either the percentage of women who will at-
Fig. 1. Costs (in millions of U.S. dollars) and effects (life-
years gained) per 1 000 000 women in a simulated general
population per year for nearly 500 simulated screening
policies (each represented by a dot) differing with respect
to age range, screening interval, and number of scheduled
screening examinations in a lifetime. The analysis consid-
ered a 3% discount rate to convert future costs and health
effects to their present values.
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tend a recommended screening examination (screening atten-
dance) or sensitivity of the screening test will not only affect the
choice of the number of screening examinations to be offered per
woman but will also affect the choice of the age range and time
interval between the scheduled examinations (43). Higher atten-
dance and/or sensitivity will make longer intervals between
screenings and, simultaneously, broader age ranges more favor-
able in terms of cost-effectiveness because the role for a subse-
quent screening to detect abnormalities previously missed would
be less important (Table 3).
A lower specificity will increase the incremental costs per
life-year gained and, therefore, lead to a lower number of sched-
uled examinations that would be offered per woman to achieve
the same incremental cost per life-year gained compared with
Fig. 2. Schematic representation of the simulated efficient frontier showing the location of optimal starting ages, number of scheduled examinations, and screening
intervals. Costs (in millions of U.S. dollars) and effects (life-years gained) are per 1 000 000 women in the simulated general population per year of the screening
program. The analysis considered a 3% discount rate to convert future costs and health effects to their present values. The starting ages are shown as a range in years.
The interval between scheduled Pap smears is shown in years. Broken lines represent the boundaries between the age ranges and scheduled intervals.
Table 1. Efficient policies, estimated by MIcrosimulation SCreening ANalysis (MISCAN)*, characterized by the number of scheduled
examinations, screening interval, and age range and expressed as the cost and effects per woman per year of the screening program, the effects
of the program per woman during her lifetime, the cost-effectiveness ratio (CER), and the incremental cost effectiveness ratio (ICER)
No. of
scheduled
exams
Interval
between
exams, y
Age
range, y
Costs Effects Effects CER ICER†§
U.S. dollars per woman
per year of screening
(no discounting)‡
Days gained per woman
per year of screening
(no discounting)
Days gained per woman
during lifetime
(no discounting)
Costs (U.S. dollars)
per life-year gained
(3% discounting)
Costs (U.S. dollars)
per life-year gained
(3% discounting)
2 12 40–52 0.99 0.14 11.6 6700 6700
3 9 35–53 1.42 0.19 15.5 7300 9100
4 8 32–56 1.79 0.23 18.3 7700 10 200
5 9 32–68 1.94 0.23 18.7 7900 11 800
6 7 32–67 2.27 0.25 20.3 8500 15 200
7 6 32–68 2.55 0.27 21.4 8900 17 300
8 7 27–76 2.86 0.29 22.9 9400 16 800
9 6 27–75 3.17 0.30 23.9 9900 20 800
10 5 27–72 3.54 0.31 25.2 10 600 26 300
12 5 27–82 3.79 0.32 25.4 11 000 32 300
15 4 22–78 4.93 0.35 28.1 13 000 35 000
20 3 22–79 6.35 0.37 29.6 15 500 55 700
25 21⁄2 20–80 7.43 0.38 30.8 17 500 79 500
30 2 22–80 8.49 0.39 31.4 19 400 119 000
40 11⁄2 20–79 10.88 0.41 32.4 23 900 173 700
*CER  cost-effectiveness ratio; ICER  incremental cost-effectiveness ratio; MISCAN  MIcrosimulation SCreening ANalysis (6,7).
†CER was estimated using a fictitious population of 40 million women; ICER was estimated using an enlarged simulated population to reduce random fluctuation.
‡Discounting refers to converting future costs and health effects to their present values.
§The incremental cost-effectiveness ratio is calculated by dividing the difference in costs between the next less intensive efficient screening policy with the current
screening policy by the difference in effects between these screening policies. To calculate the ICER for the screening policy with two scheduled examinations the
costs and effects of this screening policy are compared with a situation without screening.
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the baseline situation in which Dutch characteristics are incor-
porated. The choice of the number of scheduled examinations
depends on the costs of medical procedures (including screening
itself) that are generated or prevented by screening. If the costs
of Pap smears, assessment, and treatment of false-positive re-
sults and CIN generated by screening are higher than those
assumed in the baseline situation, then the cost-effectiveness
ratio of screening will be unfavorably influenced. In contrast,
higher costs for treatment of invasive cancers and advanced
disease, some of which are prevented by screening, will lower
the incremental and/or average cost-effectiveness ratio. The
fixed costs for coordinating and evaluating a cervical screening
program do not influence the incremental costs per life-year
gained. However, the average costs per life-year gained will
increase if the fixed costs are higher.
International Comparison
We next compared the screening policies from countries with
cervical cancer-screening programs or national guidelines, with
the assumption that their demographic, epidemiologic, screen-
ing, and treatment characteristics were similar to those in The
Netherlands. As shown in Fig. 3, several of the screening poli-
cies are remarkably close to the efficient frontier. However, for
several screening policies, such as those from Sweden, Den-
mark, the U.K. (16 scheduled examinations), the United States,
and Australia, alternative policies could be recommended to re-
duce costs for the same amount of life-years gained or to im-
prove effectiveness while keeping the costs the same. These
alternative policies are situated in the upper-left quadrant of the
marking for a screening policy of a country in Fig. 3. For ex-
ample, the area in which more cost-effective screening policies
are situated for the United States is identified in Fig. 3 by a
broken line. It can be seen in Fig. 3 that the policy for screening
every 4 years between ages 22 and 78 years with 15 examina-
tions has the same effects for much lower cost (yearly almost
$1 million less) than the recommendations issued by the U.S.
Preventive Task Force (10) for screening every 3 years between
ages 18 and 66 years with 17 scheduled examinations. If, how-
ever, a more intensive policy is committed to (the U.S. Preven-
tive Task Force policy is conservative compared with recom-
mendations from other U.S. authorities and current U.S. practice
that recommends annual screening), the efficient screening
policies with 20–30 examinations and an interval of 2–3 years
starting after age 20 years are more cost effective than current
practice.
To investigate whether the wide diversity in screening rec-
ommendations and official policies among countries originates
from differences in the epidemiology of cervical cancer or price
level, we compared the incidence of cervical cancer and price
levels among countries. If the background incidence is higher in
a country than it is in The Netherlands, then the effects of a
screening policy would be proportionally higher than those cal-
culated in this analysis, whereas the total costs would stay at the
same level. If the price level in a country is lower than it is in
The Netherlands, then the total costs of a screening policy would
be proportionally lower than those calculated in this analysis.
The differences in background incidence of cervical cancer and/
or price level will result in more favorable cost-effectiveness
estimates than those calculated for The Netherlands (and vice
versa, if the background incidence is lower and/or the costs are
higher), which may lead to the choice of an efficient screening
policy with a higher number of scheduled examinations despite
having the same threshold value of the incremental and/or av-
erage cost-effectiveness ratio. Differences in incidence and/or
price level may, therefore, explain the diversity in the number of
scheduled examinations among different countries.
We obtained the background incidence of cervical cancer for
each country (44–46). We calculated the price levels for each
country by dividing the health care-specific purchasing power
parities (47), which adjust the exchange rates for different coun-
tries to the health care-specific price levels by the current ex-
change rates. By comparing the incidence and the price levels to
those of The Netherlands, we obtained relative incidence and
relative price levels, respectively. These values were then plot-
ted (Fig. 4, A). The solid line represents the situation in which
the relative incidence is equal to the relative price level. For the
countries that fell above the line (Denmark and the United
States, assuming a high background incidence to be representa-
Table 2. Detailed overview of the predicted costs and effects per 1 000 000 women of the general population per year of the screening program for the efficient
screening policies as estimated by MIcrosimulation SCreening ANalysis (MISCAN), with 5, 10, 20, and 40 scheduled examinations*
No. of scheduled examinations 5 10 20 40
Interval between examinations, y 9 5 3 11⁄2
Age range, y 32–68 27–72 20–77 20–79
No. of Pap smears per year of screening 40 000 78 000 152 000 300 000
Costs† (U.S. dollars, millions)
Screening 1.74 2.94 5.05 8.66
Repeat smears 0.22 0.42 0.83 1.62
Referred, no cervical intraepithelial neoplasia (CIN)‡ 0.01 0.02 0.04 0.09
CIN§ 1.12 1.70 2.28 2.54
Invasive carcinoma‡§ −0.58 −0.80 −0.98 −1.07
Advanced disease −0.56 −0.75 −0.88 −0.96
Total costs 1.94 3.53 6.35 10.87
Effects
Prevented deaths 26 35 41 45
Life-years gained¶ 640 862 1022 1110
*MISCAN  MIcrosimulation SCreening ANalysis (6,7). The values are not discounted because no time preference is established.
†Costs determined relative to a situation without screening.
‡Costs of follow-up and treatment.
§If all invasive cases could be prevented a total U.S. $1.54 million saved, as predicted by MISCAN.
Costs of treatment for recurrence and palliative care in women who die of cervical cancer. Maximum savings on costs of advanced disease total U.S. $1.38 million.
¶The days gained per woman per year of screening can be calculated by multiplying the number of life-years gained by 365/1 000 000.
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tive), the cost-effectiveness estimates of a policy will be more
favorable than those estimates in The Netherlands. Conse-
quently, more intensive screening policies will stay below a
certain threshold value of the incremental and/or average cost-
effectiveness ratio. For the countries that fell below the line
(Australia, the U.K., Iceland, Finland, Sweden, and the United
States, assuming a low background incidence), having a rela-
tively low incidence and/or a higher price level, the cost-
effectiveness estimates will be less favorable than those in The
Netherlands.
We next plotted the combination of incidence and price level
for the different countries against the incremental cost-
effectiveness ratios for each of the respective screening policies
(Fig. 4, B). If the differences in intensity of screening among
countries can be explained by differences in incidence and/or
price level, all screening policies would be situated on a straight
line through the origin when plotted. However, it can be con-
cluded from Fig. 4, B, that the diversity in screening policies,
which range from recommending seven to 27 scheduled exami-
nations, cannot be explained by differences in incidence level or
price level.
Finally, we calculated the costs and effects of screening poli-
cies evaluated in other cost-effectiveness analyses (2,15–21)
with our MISCAN model (Fig. 5). Most policies appeared to be
close to our efficient frontier (Fig. 5). The screening policies
with intervals between screening examinations varying by age
that were found to be efficient by Gustafsson and Adami (16) are
close to our efficient frontier, as were those with fixed intervals
(screening every 7 years between ages 30 and 58 years). Eddy
(15) investigated screening every 3 years between ages 20 and
74 years, alternative ages to start screening (17, 23, or 26 years),
and alternative screening intervals (every 2 or 4 years) and con-
cluded that a minimal screening policy of every 3 years between
ages 20 and 65 years was cost efficient. However, this minimal
policy and screening every 3 years between ages 29 and 74 years
are less than efficient according to our model (Fig. 5). For this
number of scheduled examinations (16 in both cases), an interval
of screening every 4 years would be more efficient (see Fig. 2).
McCrory et al. (19) calculated the costs and effects for three
screening policies based on conventional Pap smears that started
at age 18 years and had a screening interval of every 1, 2, or 3
years. The screening policies with a screening interval of every
2 or 3 years, which we included in our analysis, appeared to be
close to the efficient frontier. The screening policy with a 1-year
interval was omitted, as no screening policies with more than 40
scheduled examinations were included in our analyses. Although
Table 3. Sensitivity analysis: Incremental cost-effectiveness ratios, expressed as U.S. dollars per life-year gained, with 3% discounting to
convert future costs and health effects to present values*
No. of scheduled Pap smears 5 10 20 40
Interval, y 9 5 3 11⁄2
Age range, y 32–68 27–72 20–77 20–79
low† high low high low high low high
Background incidence 24 400 5100 49 800 11 400 124 300 26 800 331 700 83 600
Attendance 14 500 10 800 16 200 33 300 33 300 81 500 80 100 315 400
Sensitivity of screening test 19 200 9300 19 200 32 000 41 700 66 500 117 300 191 000
Specificity of screening test 13 500 11 000 30 100 24 400 64 300 51 400 206 300 157 400
Screening costs 7000 21 400 16 100 46 700 34 800 97 600 107 200 306 600
Treatment costs, CIN and false positives‡ 10 200 15 100 23 700 31 500 51 400 64 400 167 300 186 600
Treatment costs, invasive cancers 13 100 9200 27 700 23 400 57 200 52 700 175 200 170 600
Baseline§ 11 800 26 300 55 700 173 700
*Sensitivity analysis is defined as investigations that isolate key parameters involved in the cost-effectiveness analysis that indicate the degree of influence each
key parameter has on the outcome of the analyses. Incremental cost-effectiveness ratios are calculated by comparing the costs and effects of a screening policy with
five scheduled examinations to one with four scheduled examinations, 10 scheduled examinations to one with nine scheduled examinations, 20 scheduled
examinations to one with 15 scheduled examinations, and 40 scheduled examinations to one with 30 scheduled examinations.
†The background incidence (defined as the incidence in a situation without screening) and fixed costs, screening costs, and treatment costs were halved and
doubled to obtain the low values and high values, respectively. To determine attendance, the lack of attendance values were halved and doubled to obtain the high
estimates and low estimates, respectively. To determine the sensitivity of the screening test, the proportion of false-negative results for all stages was halved and
doubled to obtain the high estimates and low estimates, respectively. The high values for the specificity of the screening test were obtained by halving the percentage
of repeat smears because of borderline test results and the proportion of attending women that are referred for a colposcopy and a biopsy after which no cervical
neoplasia is found. The low values for the specificity of the screening test were obtained by doubling the baseline estimates for these parameters.
‡CIN  cervical intraepithelial neoplasia.
§The baseline estimates for the background incidence for women willing to participate in screening were 0.0229 for those born from 1889 through 1918; 0.0235
for those born from 1919 through 1928; 0.128 for those born from 1929 through 1938; 0.0106 for those born from 1939 through 1948; and 0.0148 for those born
from 1949 through 2000. For attendance the baseline estimate was 80%. The sensitivity was assumed to be 80% for preinvasive CIN, 85% for preclinical invasive
stages IA and IB, and 90% for preclinical invasive stage II+ at baseline. The specificity assumed that 0.06% of attending women are referred for a colposcopy and
a biopsy after which no cervical neoplasia is found, and that 6.2% of attending women will, on average, have 1.8 repeat smears because of borderline test results
after their primary smear and before they return to the regular screening schedule. The baseline estimates for the screening costs decrease from U.S. $32 per smear
if 80 000 smears were taken annually to U.S. $26 per smear if 2 500 000 smears were taken annually. The invitation costs were U.S. $1 per invitation at baseline.
The baseline estimates for the costs of diagnosis and treatment of CIN and false positive results are U.S. $1950 and U.S. $485, respectively. The costs for diagnosis
and treatment of invasive cancers at baseline are U.S. $5315, U.S. $11 265, U.S. $10 620, and U.S. $9705 for diagnosis and treatment of invasive cancers stage IA,
IB, screen-detected II+, and clinically diagnosed II+, respectively. The costs for treatment (including palliative care) for advanced cervical cancer are age dependent;
U.S. $30 800 for women aged less than 50 years, U.S. $21 955 for women aged between 50 and 70 years, and U.S. $9345 for women aged more than 70 years at
baseline.
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the screening policy also may have appeared to be quite close to
the efficient frontier, the incremental and/or average cost-
effectiveness will be far outside the range that we considered to
be acceptable. The screening policies considered by Waugh (21)
(screening every 3 years between ages 20 and 59 years and
screening every 5 years between ages 20 and 60 years) and
Sherlaw-Johnson (20) (screening every 3 years between ages 18
and 64 years) and some of the screening policies considered
optimal by Gyrd-Hansen (17) (varying from five scheduled ex-
aminations between ages 30 and 50 years to 28 scheduled ex-
aminations between ages 25 and 69 years) were not efficient
according to our model.
DISCUSSION
The results show that efficient screening policies for cervical
cancer can be characterized by an average screening age of about
50 years. This means that an intensive screening policy would
begin at a younger age, end at an older age, and have a shorter
interval between the scheduled examinations.
With the use of the MISCAN program, we determined a
predicted gain in life expectancy of 46 days if cervical cancer is
eliminated. This gain is small compared with the predicted in-
crease in life expectancy of other diseases, such as the approxi-
mately 1.5 years if coronary heart disease were eliminated in
women (48), and is directly related to the relatively low mor-
tality rate from cervical cancer. However, it is more relevant to
compare the gain in life expectancies with different health in-
terventions because most health interventions can only partly
eliminate the disease. Also, elimination or near elimination of
cervical cancer through screening does not seem possible con-
sidering the persistent level of nonattendance of women at high
risk for cervical cancer. Because we based our model on the
Dutch cervical cancer-screening figures, we assumed an atten-
dance of about 80%. Half of the remaining 20% are persistent
nonattenders. The nonattenders were assumed to be at high risk
for cervical cancer and accounted for 25% of the cervical cancer
mortality, putting the upper limit of attainable gain in life ex-
pectancy by cervical cancer screening at 75% of 46 days or a
total of 34 days.
Our predictions show that the efficient screening policies that
range from two to 40 scheduled examinations result in a gain in
life expectancy from 12 to 32 days. Wright and Weinstein (49)
reviewed gains in life expectancy from a variety of health in-
terventions and found estimates on a gain in life expectancy of
0.8 months for women aged 50–60 years who are offered bien-
nial mammography and of 8 months for women aged 35 years
who quit cigarette smoking. Our estimates for the effects of
cervical cancer screening are at the lower side of this range.
However, in addition to the effects, costs also must be consid-
ered when evaluating diverse health interventions. Cost-
effectiveness ratios as estimated in this study express the trade-
off between costs and effects of interventions (50).
There are several limitations associated with cost-effec-
tiveness analyses, including random fluctuation and outcome
uncertainty (41). Random fluctuation complicates the determi-
nation of the efficient screening policies because repeat estima-
tions of costs and effects may yield different estimates for the
costs and effects that result in small differences in screening
Fig. 3. Comparison of the costs (in millions of U.S. dollars) and effects (life-
years gained) per 1 000 000 women in the general population per year of screen-
ing for screening policies used in countries with a cervical screening program or
program recommended in national guidelines and the simulated efficient fron-
tier, with 3% discounting. Discounting refers to converting future costs and
health effects to their present values. The solid line represents the simulated
efficient frontier. The numbers of scheduled lifetime Pap smears are identified
with solid filled circles. NL/F  The Netherlands from 1996/Finland (8)
(7/5/30–60, where 7 is the number of scheduled Pap smears, 5 is the screening
interval in years, and 30–60 is the age range); NL  The Netherlands before
1996 (7/3/35–53); DK  Denmark (9), (13/3/23–59); S  Sweden (13)
(12/25/25–58); ICE Iceland (12) (19/21⁄2/25–70); UK(3) United Kingdom
(11) (16/3/20–65); UK(5) United Kingdom (11) (10/5/20–65); US United
States (10) (17/3/18–66); AUS  Australia (5) (27/2/18–70); WHO  World
Health Organization/Eurogin (14) (14/3/25–64).
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policies determined to be efficient. This was illustrated by the
screening policy including seven scheduled examinations be-
tween ages 27 and 68 years, which was found to be efficient
in our initial predictions but not after enlarging the simulated
population.
Outcome uncertainty is related to both parameter and model
uncertainty. Parameter uncertainty is the uncertainty about the
true values of the input parameters, whereas model uncertainty
involves the way these parameters are modeled. An example of
model uncertainty is that we made the assumption that costs for
coordinating and evaluating a cervical screening program were
fixed and thus that these costs were independent of the number
of scheduled examinations. Increasing the coordinating and
evaluating costs with the number of scheduled examinations will
decrease the incremental cost-effectiveness ratio for screening
policies with a small number of examinations but will increase
the incremental cost-effectiveness ratio for more intensive
screening policies.
In addition to the study design limitations, our results would
be influenced if quality-adjusted life-years gained were used
instead of life-years gained to include any side effects of the
intervention. The negative side effects of screening, including
those on quality of life, are largely proportional to the number
of screening examinations. By contrast, the favorable effects of
screening follow the law of diminishing returns. Combining the
negative side effects and the favorable effects of screening in
terms of quality-adjusted life-years will result in a rapid decrease
in the number of incremental quality-adjusted life-years gained
for screening policies with an increase in the number of exami-
nations (24), and eventually any additional intensifying screen-
ing will decrease the net health effects. Uncertainty analysis
and quality-of-life considerations are both subjects of ongoing
research.
The present cost-effectiveness estimates are obtained for a
model that aimed to be representative of cervical cancer screen-
ing in The Netherlands. Different demographic, epidemiologic,
and screening characteristics led to changes in the choice of the
number of Pap smears offered per woman, the choice of the age
range to be screened, and the time period between the scheduled
number of Pap smears. However, we found (Fig. 4, B) that the
diversity in the number of scheduled examinations in currently
used or recommended screening policies, which varied from
Fig. 4. A) Comparison of the incidence of cervi-
cal cancer and health care-specific price levels of
seven countries (Australia, Denmark, Finland,
Iceland, Sweden, the United States, and the U.K.)
relative to The Netherlands. The relative inci-
dence level is calculated by dividing the inci-
dence in a situation before screening by the Dutch
incidence in a situation without screening. The
relative price level is calculated by dividing the
price level of a country by the Dutch price level.
Price levels are calculated by dividing health
care-specific price levels by the exchange rates.
B) Ratios of incidence of cervical cancer to price
level relative to The Netherlands and incremental
cost-effectiveness ratios of cervical screening
policies used or recommended in Australia, Den-
mark, Finland, Iceland, Sweden, the United
States, and the U.K. The solid line represents all
situations with the same incremental cost-
effectiveness ratio as The Netherlands, after cor-
rection for incidence and price level. The dotted
lines indicate all situations with two (lower line)
or four (upper line) times the incremental cost-
effectiveness ratio of The Netherlands. For the
incremental cost-effectiveness ratios of screening
policies used or recommended, comparisons are
made between the efficient screening policies
with the same number of scheduled examinations.
AUS  Australia; DK  Denmark; F  Fin-
land; ICE  Iceland; S  Sweden; US-I 
United States, Second National Cancer Survey
1947; US-II US-Connecticut Tumor Registry;
UK United Kingdom; UK (3) UK screening
every 3 years; UK(5)  UK screening every 5
years.
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seven to 27 examinations, cannot be explained by differences in
the incidence of or price level in the countries involved. A factor
that may influence the age range is the age-specific incidence
of invasive cervical cancer, which reflects the age-specific inci-
dence of progressive CIN. By comparing the age-specific inci-
dence among different populations, Gustafsson et al. (44) found
that, in addition to differences in the level of cervical cancer
incidence, there were two patterns of age-specific incidence. In
the first pattern, illustrated by some European countries, includ-
ing The Netherlands, the peak age-specific incidence of invasive
cervical cancer occurs at a younger age and declines rapidly
thereafter. In the second pattern, illustrated by the United States,
New Zealand, and Asian and African countries, the peak age-
specific incidence of invasive cervical cancer occurs at an older
age and declines slowly thereafter. Therefore, in countries where
the initial peak in age-specific incidence occurs at an older age,
there will be a shift in the estimated optimal screening starting
age, moving upward, to an older age, and/or to lengthening the
screening interval. Thus, when considering the incidence of in-
vasive cervical cancer in the United States and Australia, it is
unclear why screening policies that have short screening inter-
vals and that start at a young age are recommended. Possible
differences among countries in the implicit threshold values of
the acceptable incremental and/or average cost-effectiveness ra-
tio provide no plausible explanation for the diversity in screen-
ing policies. The diversity, therefore, originates from other
sources, including, for example, the rationality of the recom-
mendation process, the data and evidence used in choosing
among policies, or the methods used in evaluating policies. The
latter is illustrated by the fact that even though policies evaluated
in other cost-effectiveness studies (24) were close to our effi-
cient frontier (Fig. 5), the estimated incremental and/or average
cost-effectiveness ratios differed considerably among studies
(24) and may, subsequently, have led to different elected screen-
ing policies.
Moreover, our model considers features that were not con-
sidered in other cost-effectiveness analyses (24); this may have
contributed to the different cost-effectiveness estimates. First, in
our model both costs and effects were discounted to the start of
screening at a rate of 3% (41). Second, we assumed that nonat-
tendance is associated with an increased risk of cervical cancer
(25–27). Third, we accounted for the fact that the population is
already screened to a certain extent. Our assumption leads to
a lower prevalence of preclinical disease and, consequently, to a
lower baseline risk for cervical cancer at the start of the screen-
ing program. Therefore, our cost-effectiveness estimates will be
less favorable.
The current cost-effectiveness analyses concern high-income
countries. However, in low-income countries in Southern
America, Africa, and Asia, the incidence and cancer-related
death rate from cervical cancer is much greater than the “high”
incidence selected in our sensitivity analyses. Although the in-
cidence of cervical cancer can be reduced by a Pap smear-based
screening program, such a program is often not feasible in low-
income countries because it requires a high degree of organiza-
tion with cytologic laboratories and personnel. An alternative for
Fig. 5. Comparison of the costs (in millions of U.S. dollars) and effects (life-
years gained) per 1 000 000 women in a simulated general population per year of
screening for screening policies considered in other cost-effectiveness analyses.
Comparison is made with the simulated efficient frontier with 3% discounting.
Discounting refers to converting future costs and health effects to their present
values. -  Hristova and Hakama (18) (7/5/30–60, where 7 is the number of
scheduled Pap smears, 5 is the screening interval in years, and 30–60 is the age
range); + Gyrd-Hansen et al. (17) (5/5/30–50; 7/5/30–60; 8/5/25–60; 8/4/30–
58; 9/4/25–57; 12/4/25–69; 13/4/20–68; 13/4/20–68; 18/3/20–68; 25/2/20–68;
28/2/15–69);H17009 Eddy (15) (16/3/29–74; 15/4/20–76; 17/3/26–74; 16/3/20–65;
18/3/23–74; 19/3/20–74; 20/3/17–74; 28/2/20–74); ×  Waugh and Robinson
(21) (14/3/20–59; 9/5/20–60); *  Sherlaw-Johnson (20) (15/3/18–63);  
International Agency for Research on Cancer (IARC) (2) (9/5/25–65; 14/3/25–
64);   IARC (2) varying intervals indicated by * and all screening ages
(10/*/25,26,30,36,40,45,50,55,60,65; 15/*/25,26,29,32,35,38,41,44,47,50,53,56,
59,62,65);   Gustafsson and Adami (16) (5/7/30–58);   Gustafsson and
Adami (16) varying intervals indicated by * (1/*/37; 2/*/34,45; 3/*/32,40,51;
4/*/31,37,44,57; 5/*/30,35,43,50,60; 7/*/28,33,37,43,49,57,66; 10/*/
26,30,33,37,42,46,51,57,63,70; 15/*/23,27,30,32,35,38,41,44,48,51,55,60,64,69,74;
20/*/22,25,28,30,32,34,36,38,40,43,46,49,52,55,58,62,65,69,73,78); –  McCrory
(19) (20/3/18–75; 30/2/18–76). An upper age for screening of, respectively, 76 and
75 years was assumed, although no upper age limit was mentioned in the study.
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Pap smear screening in developing countries may be aided
visual inspection of the cervix, which has a sensitivity similar to
Pap smears but a lower specificity (51,52). A specific cost-
effectiveness analysis to investigate the possibility of a screen-
ing program based on aided visual inspection in low-income
countries is warranted.
Although the present analyses are based on Pap smear screen-
ing, which is the conventional method for detection of cervical
lesions in large-scale settings, there are new methods for the
detection of cervical cancer; for example, screening for the pres-
ence of oncogenic variants of the human papillomavirus. The
cost-effectiveness of screening for human papillomavirus is not
yet known (53). Other developments involve new diagnostic
technologies in cytopathology, such as liquid-based cytology
and computer-aided imaging. In the future, these or other new
developments may lead to improvements in test characteristics
and/or changes in costs, which would require reconsidering the
optimal screening policies. Because women who are regularly
screened at the appropriate ages already have a reduced risk of
cervical cancer, the gain in cost-effectiveness of cervical cancer
screening must arise from reducing the overall costs and sim-
plifying the screening process by reducing the number of false-
positive results. The great breakthrough in the latter has to come
from methods that are able to distinguish progressive and re-
gressive disease.
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